increase the immune response to the antigens following immunization.
In the early 1900s, infections by Clostridium tetani and Corynebacterium diphtheriae were serious health issues owing to the pathology that is induced by tetanus and diphtheria toxins, respectively (Timeline). Immunization with conjugates of toxin and antibody, which were referred to as toxin-antitoxin, yielded better protection and fewer side effects than low-dose toxin alone 1 , and it was proposed that the antitoxin enhanced the immune response of the recipient by slowly releasing antigen over time. In the following years, further improvement came with the production of toxins that had been inactivated with formalin or heat (referred to as toxoids), which could be used for immunization 2, 3 . In 1926, Alexander T. Glenny and colleagues reported that precipitation of antigen onto insoluble particles of aluminium potassium sulphate
, known as 'potash alum' , before immunization produced better antibody responses than soluble antigen alone, providing the first clue to the adjuvant properties of aluminium salts 4 . Following this discovery, aluminium salts were used in vaccine preparations with tetanus and diphtheria toxoids to protect against C. tetani and C. diphtheriae, respectively, and today insoluble aluminium salts are used worldwide as the principle adjuvants in clinical vaccines.
Glenny believed that aluminium salts were effective adjuvants because they allowed antigen to remain in the body for a long time and because the antigen was slowly released from the insoluble salt Abstract | The efficacy of vaccines depends on the presence of an adjuvant in conjunction with the antigen. Of these adjuvants, the ones that contain aluminium, which were first discovered empirically in 1926, are currently the most widely used. However, a detailed understanding of their mechanism of action has only started to be revealed. In this Timeline article, we briefly describe the initial discovery of aluminium adjuvants and discuss historically important advances. We also summarize recent progress in the field and discuss their implications and the remaining questions on how these adjuvants work.
Timeline | History and important scientific advances of aluminium adjuvants
First use of toxin-antitoxin for human immunization 1 (1910) (1911) (1912) (1913) (1914) (1915) (1916) (1917) (1918) (1919) ) New York City averages 14,000 cases of diphtheria and 1,290 deaths per year 58 (1920) (1921) The average annual number of diphtheria cases in the United States is 175,885* Aluminium precipitation enhances antibody response to diphtheria toxoid in guinea pigs 4 Immunization of guinea pigs with aluminium salt and pollen extracts increases allergic sensitization 60 (1942) (1943) (1944) New York City averages 300 cases of diphtheria and 10 deaths per year; >99% reduction in mortality from 1910 (ref. 58) Alexander T. Glenny awarded the Addingham Gold Medal and Jenner Medal 61 Immunization with diphtheria toxoid is protective against diphtheria 2 Aluminium salt enhances diphtheria toxoid immunization in humans 59 Alhydrogel becomes commercially available (E. Lindblad, personal communication)
Alexander T. Glenny elected to the Royal Society 61 *See Centers for disease control and prevention website. APC, antigen-presenting cell; IL, interleukin; MyD88, myeloid differentiation primary-response gene 88; NLRP3, NLR family, pyrin domain containing 3; T H 2, T helper 2; TRIF, TIR-domain-containing adaptor protein inducing IFNβ. 1910 IFNβ. 1913 IFNβ. 1921 IFNβ. 1926 IFNβ. 1932 IFNβ. 1934 IFNβ. 1939 IFNβ. 1944 IFNβ. 1953 IFNβ. 1955 IFNβ. 1985 IFNβ. 1989 IFNβ. 1996 IFNβ. 1942 IFNβ. 1920 Characterization of cells surrounding the 'alum granuloma' (ref. 11) Aluminium salts enhance antigen presentation by APCs 15 Aluminium salt 'primes' B cells to flux calcium when stimulated through MHC class II molecules 38 Aluminium-salt-induced IgE requires IL-4 (ref. 35) T H 2-type CD4 + T cells are preferentially primed by aluminium adjuvants 5 Uric acid acts as an adjuvant for co-administered particulate antigen 49 Uric acid and NLRP3 inflammasome implicated in aluminium adjuvant effects in vivo 7, 8, 14, 23 (2001-2006) Aluminium adjuvant effects do not require IL-1, IL-18, MyD88 or TRIF 19, 20, 30, 44 particles, which allowed prolonged and effective stimulation of the immune system, an effect referred to as the 'depot effect' . For approximately 60 years, this explanation was dogmatically accepted within the field, and only a few basic research papers on aluminium salts were published, often decades apart.
In the past two decades or so, interest in aluminium salts has reignited, and since 2007 there has been a flurry of activity aimed at understanding the adjuvant action of these compounds. In addition to or in contrast to the depot effect, insoluble aluminium salts activate innate immune cells in a manner that ultimately results in a T helper 2 (T H 2)-type immune response 5 . In 2008 it was suggested that the cytotoxicity of aluminium salts leads to the release of uric acid in vivo, which acts as a damageassociated molecular pattern (DAmp, reviewed in ref. 6) that is required for the adjuvant activity of aluminium 7 . A separate paper showed a requirement for caspase 1 activation in vivo, which is mediated by nlr family, pyrin domain containing 3 (nlrp3; also known as nAlp3) and apoptosis-associated speck-like protein containing a CArD (ASC; also known as pYCArD), collectively known as the nlrp3 inflammasome 8 
However, the field is not without controversy. other studies have failed to confirm a requirement for uric acid in vitro or for activation of the nlrp3 inflammasome in vivo, and research in these areas is ongoing. Challenges to the depot theory Glenny's proposal that the adjuvant activity of aluminium salts was due to antigen persistence and prolonged release was not without basis. Initial evidence showed that precipitated toxoid persisted for several days 9 , much longer than soluble toxoid. A subsequent study found that 7 weeks after immunization, alum nodules that were excised from one guinea pig and were ground up could be used to immunize a second guinea pig 10 . experiments by white et al. 11 showed that immunization of rabbits with antigen plus aluminium salts induced the appearance of B-cell blasts in the draining lymph nodes within 7 days of immunization and at the site of the granuloma by day 14. However, few B-cell blasts remained in the draining lymph nodes after 3 weeks, which implies that antigen is no longer being presented in the lymph nodes and that negligible amounts of antigen escape the site of injection after ~2 weeks 11 . These results are consistent with data from other studies that showed that removal of the antigen-aluminium salt nodules 14 days after immunization had no effect on the subsequent antibody titres 12 . Therefore, these data indicate that aluminium salts do not function simply by providing a long-lived antigen depot.
more recent experiments have shown that within hours of administration of aluminium salts to mice, pro-inflammatory mediators, such as interleukin-1β (Il-1β) 13 , CC-chemokine ligand 2 (CCl2; also known as mCp1), CCl11 (also known as eotaxin) 7 , histamine and Il-5 (A.S.m., unpublished observations), are detectable. Also, innate inflammatory cells, such as neutrophils, eosinophils, inflammatory monocytes, myeloid dendritic cells (DCs) and plasmacytoid DCs, are recruited to the site of aluminium salt injection within 1 day 7 . Although the mediators that contribute to the recruitment of these infiltrating cell types have not yet been completely defined these data clearly show that aluminium salts have additional effects that account for their adjuvant properties.
Aluminium salts and innate immunity
Effects of aluminium salts on antigenpresenting cells. The ability of aluminium salts to promote antigen uptake and presentation by human macrophages was first demonstrated over 20 years ago 15 . more recently, it has been shown that exposure of peripheral blood mononuclear cells (pBmCs) to aluminium salts in vitro leads to their upregulation of mHC class II molecules, CD40 and CD86 (ref. 16) . Studies using mouse DCs in vitro have yielded some conflicting results, with one study finding that aluminium salts did not induce the expression of co-stimulatory molecules or enhance antigen presentation 17 , but another showing that CD86 was upregulated and antigen presentation by DCs was increased 18 . An in vivo study found that peritoneal DCs and B cells internalized antigen that was adsorbed to aluminium salts more readily than soluble antigen alone, and aluminium salt increased the expression of CD86 by DCs 7 . In addition, peritoneal injection of aluminium salt induced the recruitment of monocytes to the peritoneum. In the presence of aluminium salts, these monocytes acquired antigen, trafficked to the draining lymph node and differentiated into CD11c + mHC class II + DCs in a myeloid differentiation primaryresponse gene 88 (myD88)-dependent manner. These recruited monocytic DC precursor cells (and not lymph-node-resident or spleen-resident DCs) were shown to be responsible for priming naive CD4 + T cells in the lymph node.
Box 1 | Different insoluble aluminium salts have distinct characteristics
Several insoluble aluminium salts are used as adjuvants in human and animal vaccines, but the term 'alum' only applies to aluminium potassium sulphate (reviewed in ref. 46) (see the table) . Alum was used by Alexander Glenny and captures antigen by precipitation when the solution is neutralized. Owing to problems in manufacturing reproducibility, alum has been almost completely replaced by aluminium hydroxide and aluminium phosphate for commercial vaccines. These can be prepared in a more standardized manner and capture antigen by direct adsorption. Many types of adsorptive interactions occur between the antigen and the adjuvant, but two adsorption forces seem to predominate 46 . The first, electrostatic interactions, occurs most strongly between negatively charged proteins and aluminium hydroxide, and between positively charged proteins and aluminium phosphate. The second, anionic ligand exchange, is a covalent interaction that occurs when phosphates from an antigen substitute for hydroxyl groups on the adjuvant. 19, 20 . In the first study, myD88-deficient mice produced normal amounts of IgG1 and, interestingly, excessive amounts of Ige in response to immunization with antigen and aluminium salts 19 . The second study used mice that were deficient for both myD88 and TrIF, which therefore could not signal through Tlrs 20 . In this case, antigen-specific antibody responses of all isotypes induced following vaccination with the antigen trinitrophenyl-haemocyanin and aluminium salt were comparable to those observed in control mice. Although the use of haemocyanin slightly confounds the interpretation of these results, as haemocyanin itself has adjuvant properties that might be Tlr independent, together these studies strongly suggest that the antigen-specific antibody response to aluminium salts does not depend on Tlrs.
It was recently shown that monosodium urate (mSu) crystals, which are formed when the concentration of uric acid is saturating
, bind to DCs in an unconventional manner 21 . using atomic force microscopy to measure interaction force, mSu crystals were found to interact strongly with the plasma membrane, even when surface proteins were removed. This occurred through a direct interaction with cholesterol and potentially other lipids. So, it is possible that DCs or other phagocytic cells bind to aluminium salts through a similar mechanism, but this has yet to be determined experimentally. latex beads were also shown to interact strongly with the membrane of phagocytes, but basic calcium phosphate crystals and allopurinol crystals did not produce detectable interaction forces 21 . Therefore, it is currently an open question whether aluminium salts interact with cells through a specific and unidentified receptor or through a less conventional manner, similarly to mSu crystals.
NLRP3 inflammasome activation: direct or indirect?
Several reports showed that in vitro exposure of cells to aluminium salts induced the activation of caspase 1 and the release of its known downstream targets, Il-1β, Il-18 and Il-33 (refs 18,22,23) . These reports and subsequent studies 8, 14, 24, 25 showed that nlrp3 and ASC are required for the activation of caspase 1 and its target cytokines. macrophages primed with lpS and exposed to aluminium salts in vitro produced Il-1β, as well as Il-18 and Il-33 in studies that examined the production of these cytokines, in a nlrp3-and caspase 1-dependent manner 8, 23, 24 (fiG. 1) .
Intact endocytic machinery 8, 22 and subsequent potassium efflux 8 , which is a known co-activator of caspase 1, are thought to be required for this Il-1β production. However, the ATp receptor p2X 7 (a purinergic receptor), which is known to also have a role in the activation of the nlrp3 inflammasome, was not involved in Il-1β production in these studies 8, 24 . related reports have shown that other particulate materials, such as silica, asbestos and mSu crystals, also act through the nlrp3 inflammasome to produce Il-1β 14, 26, 27, 52 . Together, these data suggest that aluminium salts and other particulates can initiate caspase 1 activation through the nlrp3 inflammasome. However, given that aluminium salts can induce an antibody response in the absence of Tlr signalling adaptor molecules 19, 20 , it remains unclear why a Tlr signal, such as that induced by lpS, is required for the production of pro-Il-1β and the activation of caspase 1 in vitro 8, [22] [23] [24] .
Box 2 | The NLRP3 inflammasome and the immunomodulatory activity of uric acid NLR family, pyrin domain containing 3 (NLRP3; also known as NALP3) is a member of the nucleotide-binding domain and leucine-rich repeat containing gene (NLR) family and is an intracellular protein that can sense various pathogens, such as Listeria monocytogenes and Staphylococcus aureus, pathogen products, such as lipopolysaccharide (LPS) and muramyl dipeptide, and crystals, such as monosodium urate (MSU) and calcium pyrophosphate dihydrate 47 . When activated, NLRP3 associates with the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC; also known as PYCARD), which interacts with inactive pro-caspase 1. This facilitates the autocatalysis of pro-caspase 1 and results in the generation of active caspase 1. In vitro, expression of pro-interleukin-1β (pro-IL-1β) and activation of caspase 1 depend on Toll-like receptor (TLR) signalling, which is usually triggered by LPS. Caspase 1 cleaves pro-interluekin-1β (IL-1β), pro-IL-18 and pro-IL-33 to generate the active cytokines, which are then secreted through a non-canonical secretion pathway that is poorly understood. For a simplified version of what is known about the action of the NLRP3 inflammasome, see the figure.
Uric acid is a catabolic product of nucleotides and is soluble at high concentrations within cells. Cell damage or death causes the release of uric acid into the extracellular milieu, where it is much less soluble and forms MSU crystals, which are the causative agent of gout 48 . Uric acid has been shown to have adjuvant activity when co-injected with particulate antigen 49 . However, this activity only occurred above saturating levels, strongly implying that MSU crystals and not soluble uric acid function as the adjuvant. Uric acid promotes CD4 + and CD8 + T-cell responses 50, 51 , as well as antibody responses 28 . In vitro, stimulation of a monocytic cell line or of peritoneal macrophages with MSU crystals led to the secretion of IL-1β and IL-18, and this required all three components of the NLRP3 inflammasome: NLRP3, ASC and pro-caspase 1 (ref. 52). MyD88, myeloid differentiation primary-response gene 88; P2X 7 , a purinergic receptor. Nature Reviews | Immunology How do aluminium salts activate the nlrp3 inflammasome? At present there are two different models, both of which are compatible with the finding that phagocytosis is required for this process. In the direct activation model, phagocytic cells directly engage and engulf aluminium salt particles 14 . It is currently unclear whether this occurs through the interaction of aluminium salt particles with a specific receptor on the surface of phagocytic cells or through their non-specific adsorption to cell-surface molecules (see above), as has been shown with mSu crystals 21 . This engulfment leads to lysosomal damage and rupture, followed by the release of antigen and lysosomal enzymes such as cathepsin B into the cytoplasm. In some studies, the release of Il-1β was found to depend partially on cathepsin B activity and to depend strongly on nlrp3 and ASC 14, 13 . rupture of endolysosomes by silica crystals and osmotic shock produced similar results, suggesting that aluminium-salt-induced lysosomal damage may activate a default pathway that senses intracellular danger.
The indirect activation model proposes that aluminium salt cytotoxicity leads to the release of endogenous DAmps such as uric acid
, which results in the activation of the nlrp3 inflammasome. Following intraperitoneal injection of aluminium salts and antigen into mice, the local concentration of uric acid was shown to increase substantially 7 . Furthermore, pre-treatment of mice with uricase to degrade uric acid inhibited CD4 + T-cell priming. presumably, aluminium salts cytotoxicity causes uric acid release and the formation of mSu crystals, which could then be sensed by macrophages or other leukocytes to initiate innate and adaptive immune responses.
notably, the study did not report what effect, if any, the uricase pre-treatment had on antibody titres, even though mSu crystals had been previously reported to enhance antibody responses to co-injected antigen 28 and antibodies are thought to provide the primary protective mechanism induced by aluminium salts. There are also other questions regarding the role of uric acid. First, in vitro treatment of cells with uricase did not prevent aluminiumsalt-induced Il-1β release 8, 14, 25 . Second, the induction of inflammation and the adjuvant action of mSu crystals is reported to require Il-1-Il-1 receptor (Il-1r) engagement and the myD88 signalling pathway 29 . However, the adjuvant activity of aluminium salts does not seem to require either myD88 (ref. 20) (see above) or Il-1-Il-1r engagement in vivo 30, 31 (see below). Therefore, it remains to be elucidated why uric acid is dispensable for aluminium-salt-induced inflammation in vitro but is required in vivo and whether there is any requirement for uric acid in antibody production following immunization with aluminium salts.
Aluminium salts and adaptive immunity IL-4 and the T H 2-type bias. It has been known for many years that aluminium salts induce robust antibody responses. The discoveries that antibody production depends on T-cell help 32 and that T H -cell subsets with different functions exist 33 led to studies to determine the effects of aluminium salts on different T H -cell subsets. Aluminium salts were found to preferentially induce T H 2 cells 5 , which mediate the differentiation of B cells that secrete T H 2-cell-associated antibody isotypes IgG1 and Ige.
Because Il-4 production is a key feature of T H 2-cell responses in vivo 34 , its role in immune responses that are induced by aluminium salts was evaluated 35, 36 . Although immunization of Il-4-, Il-4rα-or signal transducer and activator of transcription 6 (STAT6)-deficient mice with antigen in the presence of aluminium salts did not trigger the production of Ige, the T H 2-cell-associated antibody isotype IgG1 was present in the serum, albeit at reduced levels. However, these mice also produced high titres of the T H 1-cell-associated antibody isotype IgG2a in response to aluminium salt, which was in contrast to wild-type mice. mirroring this change in antibody isotype production, antigen-specific T cells from Il-4-, Il-4rα-or STAT6-deficient mice produced normal levels of the T H 2-type cytokine Il-5, but more interferon-γ (IFnγ) than control mice. Therefore, Il-4 induced by aluminium salts has a role in promoting T H 2-cell-associated antibody production and T H 2-cell responses, but has a more important role in inhibiting T H 1-cellassociated antibody production and T H 1-cell responses. Subsequent work has shown that following immunization with antigen and aluminium salts, Il-6 also inhibits T H 1-cell-associated antibody production and T H 1-cell responses. unlike Il-4-deficient mice, however, Il-6-deficient mice had increased T H 2-cell responses, suggesting that Il-6 suppresses both T H 1-and T H 2-cell responses to aluminium-salt-containing vaccines 37 . But what cells produce Il-4 early in response to aluminium salts? one study 38 showed that aluminium salts induce the accumulation of a population of Gr1 + Il-4-producing cells in the spleen 6 days following immunization. This population comprised eosinophils and a myeloidcell type, although more recent evidence argues that it is composed mainly (~80%) of eosinophils 39 . These cells appear at the site of injection within 24 hours 40 , and Il-4 produced by these cells was shown to increase B-cell proliferation and to promote an increase in the production of Igm 38, 39 . In addition, depletion of Gr1 + cells in mice followed by administration of an aluminiumsalt-containing vaccine resulted in the generation of IgG2c-producing B cells 40 ; neutralization of Il-4 had the same effect.
Together, these studies indicate that aluminium salts promote the recruitment of Il-4-producing eosinophils to the spleen, which in turn mediate the production of early Igm. Il-4 may also be involved in increasing the accessibility of the B-cell Ige locus to factors that are required for class switching and in suppressing the events that are required for T H 1 cells to develop during priming 41 
Controversy on the NLRP3 inflammasome.
A link between aluminium-salt-induced activation of the inflammasome and the induction of antibody responses was first provided by a study by eisenbarth et al. 8 showing that vaccination with antigen and aluminium salt required nlrp3, ASC and caspase 1 to induce antigen-specific IgG1 production 8 . Soon after, a minor but important role for nlrp3 in aluminiumsalt-induced IgG1 production was reported by li et al. 23 . These studies suggested that unlike Il-4, which primarily inhibits T H 1-type responses, the nlrp3 inflammasome promotes T H 2-type responses. However, a subsequent study by Franchi et al. 24 reported the opposite result: nlrp3 deficiency did not alter the production of Igm, IgA and IgG antibodies of any isotype following immunization with aluminium salt and an antigen. our own experiments in caspase 1-deficient mice have also failed to find a defect in either T-cell or antibody responses in response to aluminium salts (A.S.m., unpublished observations). Adding further confusion, Kool et al. 25 recently showed that nlrp3-deficient mice were partially defective at priming antigen-specific T-cell-receptor-transgenic T cells but had normal levels of IgG1. It was also shown that IgG2c antibody levels were slightly increased, whereas Ige antibodies were completely absent, suggesting that nlrp3 promotes class-switching to Ige at the expense of IgG2c.
The reason for these contrasting results is unclear, but they could be the result of differences in the timing of immunizations, the forms of aluminium salt used or the genetic background of the mice. All five studies examined secondary antibody responses after priming and boosting with antigen and adjuvant. The three papers that showed a role for nlrp3 in the antibody response to aluminium salts 8, 23, 25 used mice on a C57Bl/6 background, whereas Franchi et al. 24 used mice of a mixed C57Bl/6-129 background. However, in our study we used caspase 1-deficient mice also on a C57Bl/6 background (A.S.m. unpublished observations) and did not find a requirement for caspase 1 in the induction in antibody responses. The eisenbarth et al., li et al., and Kool et al. papers also used Imject Alum (pierce, uSA), which is a non-clinical adjuvant that contains magnesium hydroxide in addition to aluminium hydroxide
, whereas Franchi et al. used aluminium hydroxide as the adjuvant and we used aluminium potassium sulphate. Current work is underway in our laboratory to determine whether differences in immunization protocols, the form of the adjuvant or the background of the mice contribute to these discrepant results.
Based on the data discussed above, we conclude that activation of the nlrp3 inflammasome is sometimes, but not always, required for aluminium salts to induce T H 2-type immune responses in vivo.
Role for caspase 1 signalling mediators. As discussed earlier, the activation of the inflammasome by aluminium salts results in the production of Il-1β and Il-18, and therefore it was thought that these cytokines may be involved in aluminium-salt-induced adaptive immune responses. Indeed, these cytokines are known to have a role in asthma, a disease that is generally considered to be driven by T H 2 cells. In addition, airway hyperresponsiveness (AHr) can be induced by sensitization with antigen and aluminium salts 42 . However, earlier studies on the role of Il-1-Il-1r signalling in AHr in the presence or absence of aluminium salts indicated that this signalling pathway was only required for the development of airway inflammation in the absence of aluminium salts 30, 31 . Indeed, in the presence of aluminium salts, Il-1-Il-1r signalling was not required for bronchoconstriction, pulmonary eosinophilia, T-cell priming or antibody responses.
Il-18, which is a pro-inflammatory member of the Il-1 family, can have either T H 1-or T H 2-cell-promoting properties depending on the system used in the study 43 .
Following vaccination with antigen and aluminium salts, Il-18 was found to be partially required for Il-4 production, whereas it was not required for antigen-specific IgG1 and Ige production, or for T-cell responses 44 . So, at present, the requirement for the nlrp3 inflammasome and caspase 1 for the induction of T H 2-cell-associated antibody Box 3 | Clues to the adjuvant action of aluminium salts from other adjuvants Important clues about the adjuvant action of aluminium salts can be gained from substances with related properties. Other particles, such as seemingly inert sepharose beads or the structural biopolymer chitin, have been shown to induce rapid eosinophilia and basophilia 53, 54 . Importantly, degradation of chitin in vitro and in vivo abrogated leukocyte infiltration 54 . Egg extract from the helminth parasite Schistosoma mansoni also induces eosinophilia 40 . Similar to the adjuvant action of aluminium salts (see main text), these egg extracts induce interleukin-4 (IL-4)-dependent B-cell priming and enhance the early IgM response to co-administered antigen, although they were shown to not act as a CD4 + T-cell adjuvant 40 . Furthermore, parasite proteases, such as the GP63 proteins that are produced by Leishmania spp. are important for parasite growth and infective ability in vivo 55 . In addition, many protein allergens are proteases, and a recent study found that papain directly activates basophils to secrete IL-4 and thymic stromal lymphopoietin 56 , which are known to promote T H 2-cell responses. In line with this observation, Leishmania mexicana that lacked cysteine protease activity induced less antigen-specific IgE production than the wild-type parasite in BALB/c mice 57 . Together, it seems that these particles and proteases share some properties with aluminium salts. This suggests that the adjuvant activity of aluminium salts may be partially due to their particle properties, which induce the release of lysosomal host proteases, and/or to some as-yet-unknown mechanisms that work synergistically to induce its T H 2-cell biased adjuvant effects. production in response to aluminium salts is still a matter of debate. However, it seems that Il-1β and Il-18, which are the beststudied caspase 1 targets, are not required for the induction of adaptive immune responses in response to aluminium salts. It is possible that Il-1β and Il-18 act redundantly in this capacity or that another member of the family (for example, Il-33) or a target of caspase 1 that has yet to be identified 45 are the crucial factors.
Outstanding questions recent studies have increased our knowledge of the biological events that are induced following the administration of aluminium salts. However, the mechanisms that are required for the subsequent induction of the adaptive immune response are still debated. Some additional questions remain to be answered and some important discrepancies need to be resolved: is there a specific cellular receptor that recognizes aluminium salts? In vivo, does aluminium-salt-induced inflammation occur indirectly owing to cytotoxicity and the release of DAmps such as uric acid, which form mSu crystals, or directly by triggering phagocytosis and lysosomal disruption? lpS is required to upregulate Il1b mrnA expression and to activate caspase 1 in vitro, but what induces these effects in vivo? Is there a biological role for the induction of Il-1β secretion and for neutrophil accumulation? Is the activation of the nlrp3 inflammasome and the activation of caspase 1 crucial for the adjuvant activity of aluminium salts? If they do have a role, which caspase 1 target (or targets) is required for the induction of an adaptive immune response? Finally, after over 80 years of research, there is still no definitive proof for Glenny's original hypothesis that the depot effect of aluminium salts contributes to their adjuvant action.
Aluminium adjuvants have been successfully used in hundreds of millions of humans since 1932, greatly decreasing morbidity and mortality with minimal toxicity. Although there are instances in which aluminium adjuvants are not protective, such as vaccination against pathogens that require T H 1-cell-mediated immunity, it is hoped that the answers to these questions will aid in improving the effectiveness of aluminium salts and speed the development of alternative adjuvants. Abstract | Many models of haematopoiesis dictate that haematopoietic stem cells make an early and irrevocable choice between lymphoid and myeloid cell fates. However, recent data show that intermediate progenitors have both lymphoid and myeloid potential, thereby refuting early theories and leading to a lack of consensus in the field. In this Opinion article we present a simple pairwise relationships model of cell fate determination that does not depend on the underlying developmental branch points that in other models dictate a preferred route (or routes) to a particular cell fate.
Haematopoiesis is an ideal system for investigating the developmental relationships between cells of an organ system: haematopoiesis was the first system for which a tissuespecific stem cell was identified, and all haematopoietic lineages can be reconstituted from a single bone-marrow-derived cell, the haematopoietic stem cell (HSC). The study of haematopoiesis began in the 1960s, when Till and mcCulloch showed that bone marrow cells injected into irradiated mice gave rise to spleen colonies 1 , and when Bradley and metcalf showed that bone marrow cells dispersed in semi-solid medium formed heterogeneous colonies 2 . later, it was realized that haematopoiesis involves interactions between developing cells and mesenchymederived stromal cells, which led investigators
